English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Dear Sir,It is still questioned the use of combination therapy with biologics and immunosuppressants in the management of severe or steroid-dependent Crohn's Disease (CD). The main concern is about the risk that a prolonged therapy may increase the incidence of lymphoproliferative disorders.1A 46 year-old man with ileocolonic CD diagnosed at the age of twenty year-old was admitted, on January 2012, to our unit for the abrupt onset of obstructive jaundice, associated with weight loss. The previous clinical course of CD was indolent in the last 20 years, and the patient maintained long periods of remission after short courses of steroids and metronidazole up to 2004, when he moved to USA for work. In USA the patient …

journal of crohn's and colitis

An unusual presentation of T-lymphoma in a Crohn's disease patient treated with combo therapy: We are willing to take a risk of serious adverse events for a doubtful benefit?